BioSpace News Archive

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the execution of a Letter of Intent with Silo Pharma Inc. (“Silo”) to grant to AIkido a worldwide, exclusive sublicense for use of peptide therapy, combined with psilocybin, in the therapeutic treatment of neuroinflammatory disease in cancer patients.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences:

OTC Markets Group Inc., operator of financial markets for 11,000 U.S. and global securities, announced Antibe Therapeutics Inc., a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has qualified to trade on the OTCQX® Best Market.

Sosei Group Corporation notes the announcement from Centessa Pharmaceuticals about its launch as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs.

Cytocom, Inc. , a leading biopharmaceutical company creating first second-generation immune therapies, today provided an update regarding its CYTO-200 portfolio of clinical programs.

REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada

-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ----